CYIOS Corporation (OTC: CYIO) Announces Leadership Transition and Engages Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors
CYIOS Corporation (OTC: CYIO) announced a leadership transition and strategic steps to strengthen its balance sheet. David Lewis has stepped down and voluntarily returned 16,560 Series D preferred shares and cancelled outstanding salary and loan obligations, simplifying the capital structure. The company said it has completed 2024 PCAOB-audited financial statements and is working with its auditor to finish two years of PCAOB-audited statements to improve transparency.
CYIOS targets increasing working capital and paying down Noir Medical Supplies’ debt by mid-2026, and plans to engage AI and SaaS advisors to scope and cost the CyioIQ AI-driven medical platform to boost efficiency and third-party distribution opportunities.
CYIOS punta ad aumentare il capitale circolante e a ridurre il debito di Noir Medical Supplies entro la metà del 2026, e prevede di coinvolgere consulenti AI e SaaS per definire l'ambito e i costi della piattaforma medica guidata da IA CyioIQ per aumentare l'efficienza e le opportunità di distribuzione da parte di terzi.
CYIOS apunta a aumentar el capital de trabajo y a pagar la deuda de Noir Medical Supplies antes de mediados de 2026, y planea contratar asesores de IA y SaaS para delinear y costear la plataforma médica impulsada por IA CyioIQ para aumentar la eficiencia y las oportunidades de distribución por terceros.
CYIOS는 운전자본을 늘리고 2026년 중반까지 Noir Medical Supplies의 부채를 상환하는 것을 목표로 하며, CyioIQ AI 기반 의료 플랫폼의 범위와 비용을 파악하기 위해 AI 및 SaaS 자문가를 고용할 계획이다. 이를 통해 효율성과 제3자 유통 기회를 높일 예정이다.
CYIOS vise à accroître le fonds de roulement et à rembourser la dette de Noir Medical Supplies d'ici la mi-2026, et prévoit de faire appel à des conseillers IA et SaaS pour définir l'étendue et le coût de la plateforme médicale Pilotée par IA CyioIQ afin d'accroître l'efficacité et les opportunités de distribution par des tiers.
CYIOS zielt darauf ab, das Working Capital zu erhöhen und die Schulden von Noir Medical Supplies bis Mitte 2026 abzubauen, und plant, KI- und SaaS-Berater zu engagieren, um den Umfang und die Kosten der CyioIQ KI-gesteuerten medizinischen Plattform abzustecken, um Effizienzsteigerungen und Drittvertriebschancen zu erhöhen.
تستهدف CYIOS زيادة رأس المال العامل وتخفيض ديون Noir Medical Supplies بحلول منتصف 2026، وتخطط لاستقطاب مستشارين في الذكاء الاصطناعي وSaaS لتحديد نطاق وتكاليف منصة CyioIQ الطبية المعتمِدة على الذكاء الاصطناعي لتعزيز الكفاءة وفرص التوزيع من الأطراف الثالثة.
CYIOS 的目标是增加营运资金并在 2026 年中前偿清 Noir Medical Supplies 的债务，并计划聘请 AI 和 SaaS 顾问，以界定并估算 CyioIQ AI 驱动的医疗平台 的范围和成本，从而提升效率及第三方分销机会。
- 16,560 Series D preferred shares returned to company
- 2024 PCAOB-audited financial statements completed
- Target to pay Noir Medical debt by mid-2026
- Engaging AI/SaaS advisors to scope CyioIQ platform
- Noir Medical debt remains until target mid-2026 payoff
- CyioIQ advisor engagement is planning-stage with no guaranteed outcomes
MELBOURNE, Australia and PALM BEACH, Fla., Oct. 21, 2025 (GLOBE NEWSWIRE) -- CYIOS Corporation (OTC: CYIO) today announced that David Lewis has stepped down from his roles with CYIOS, and as part of this transition, he has voluntarily agreed to return 16,560 Series D Preferred Shares to the Company, and cancel all outstanding salary and loan obligations. This decisive step strengthens the company’s balance sheet, simplifies its capital structure, and positions CYIOS for its next stage of growth. We wish David all the best for his next endeavor.
CYIOS is also working closely with its independent auditor to complete two years of PCAOB-audited financial statements, with 2024 being fully completed, which is an important milestone toward enhancing transparency and compliance. In parallel, the company continues to focus on increasing working capital through strategic investment initiatives aimed at paying down Noir Medical Supplies’ debt obligations, a key priority expected to be completed by mid-2026.
“These are meaningful milestones in strengthening CYIOS’ foundation for growth,” said Mr. John O’Shea, Chairman and CEO of CYIOS Corporation. “We remain committed to disciplined financial management, profitable expansion, and delivering long-term value to our shareholders.”
Mr. O’Shea is also excited to announce that CYIOS is now looking to engage Artificial Intelligence (AI) and Software-as-a-Service (SaaS) advisors to help map out CyioIQ: CYIO’s AI-Driven Medical Platform scope, architecture, design, business case, and build cost for a comprehensive AI-driven platform. This initiative aims to maximize CYIOS’s position within the medical and health supply industry. The implementation of AI is expected to streamline operations within Noir Medical Supplies, driving greater efficiency, strengthening bottom-line profitability, and unlocking potential new revenue streams through third-party distribution partnerships with other industry players. More information on this exciting development will follow.
CYIOS Corporation
CYIOS Corporation (OTC: CYIO) is a diversified holding company focused on building, acquiring, and operating innovative businesses across multiple industries, including medical supplies, technology, and fintech. Through its subsidiary Noir Medical Supplies, CYIOS continues to expand its presence in the U.S. medical distribution sector, emphasizing operational excellence and sustainable profitability.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable securities laws. These statements are based on current expectations and assumptions that involve risks and uncertainties that could cause actual results to differ materially. CYIOS undertakes no obligation to update or revise any forward-looking statements except as required by law.
Contact:
Investor Relations
CYIOS Corporation
info@cyioscorporation.com
www.cyioscorporation.com
FAQ
What did CYIOS (OTC: CYIO) announce on October 21, 2025 about leadership?
Has CYIOS completed audited financials for 2024 (OTC: CYIO)?
When does CYIOS plan to pay down Noir Medical Supplies’ debt (CYIO)?
What is CyioIQ and what will CYIOS (CYIO) do next?
How will the AI initiative affect Noir Medical Supplies and CYIO shareholders?
